

# DESCRIPTIVE ANALYSIS IN REAL-WORLD OF TREAT AND EXTEND TREATMENT OF FARICIMAB IN PATIENTS FAILING PRIOR INTRAVITREAL TREATMENTS

E. GANDULLO SANCHEZ, C.L. CRESPO MARTINEZ, A.C. RODRIGUEZ NEGRIN, C. ESPIN MARTINEZ, V. GARCIA NAVARRO, F. MADRIÑAN GONZALEZ, M. LOMBARDEO PIN, D.F. FERNANDEZ VERA.

HOSPITAL PHARMACY DEPARTMENT, COMPLEJO HOSPITALARIO UNIVERSITARIO INSULAR MATERNO-INFANTIL, LAS PALMAS DE GRAN CANARIA (SPAIN)

## Background and Importance

### Faricimab monoclonal antibody

- Blocks vascular endothelial growth factor (anti-VEGF) A and angiopoietin-antibody

### Therapeutic indications

- Wet age-related macular degeneration (AMD)
- Diabetic macular edema (DME)


### Frequency of intravitreal injections

Visual outcomes


Improvements in visual acuity

Anatomical outcomes

Decreased central retinal thickness and decrease intraretinal or subretinal fluid



Initial loading phase  
4 doses monthly



Treat-and-extend (T&E) regimen  
at different intervals until improvement  
in visual and anatomic outcomes

## Aim and Objectives

To evaluate the real-world T&E regimen with faricimab in patients with wet AMD and DME following the failure of prior treatment lines and to monitor their clinical outcomes

## Materials and Methods

Unicenter, observational, descriptive and retrospective study from September 2023 to September 2024

- Age
- Sex
- Diagnosis
- Previous treatments
- Number of doses and frequency
- Reasons for discontinuation
- Side effects

After loading doses, if there is an improvement outcomes treatment intervals can be extended to



4 weeks up (Q8)  
12 (Q12) or  
16 (Q16) weeks

Data were extracted from medical records




## Results

132 patients

♂ 52%


77±10 years

169 eyes




94 AMD and 75 DME



Number of anti-VEGF previously used



AMD



DME



No side effects reported

■ one ■ two ■ three or more ■ Loading dose ■ Q8 ■ Q12 ■ Q16 ■ Ineffective ■ Loading dose ■ Monthly ■ Q8 ■ Q12 ■ Ineffective

## Conclusion and relevance

- ✓ Faricimab at our hospital is an alternative T&E regimen for wet AMD and DME patients who are resistant to other anti-VEGF.
- ✓ In wet AMD 28% eyes and in DME 19% eyes were in T&E regimen.
- ✓ In both diagnoses, approximately 11% of cases were ineffective.
- ✓ Our experience indicates the importance of long-term follow-up. The treatment was generally well-tolerated, with no significant safety issues reported.

